Elise Siegert

List of Publications by Year
in descending order

32 papers	**1,019** citations	471509 **17** h-index	501196 **28** g-index
35 all docs	**35** docs citations	**35** times ranked	**1509** citing authors

#	Article	IF	Citations
1	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.9	142
2	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Annals of the Rheumatic Diseases, 2017, 76, 270-276.	0.9	132
3	Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Annals of the Rheumatic Diseases, 2018, 77, 1326-1332.	0.9	100
4	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Research and Therapy, 2018, 20, 17.	3.5	75
5	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology, 2018, 57, 441-450.	1.9	60
6	The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. BMC Neuroscience, 2017, 18, 19.	1.9	44
7	Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. Arthritis Research and Therapy, 2018, 20, 52.	3.5	44
8	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. Autoimmunity Reviews, 2020, 19, 102452.	5.8	43
9	Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. Journal of Rheumatology, 2016, 43, 66-74.	2.0	42
10	Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. Nutrition, 2018, 55-56, 51-55.	2.4	37
11	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1576-1582.	0.9	31
12	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	1.9	27
13	Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication. Journal of Rheumatology, 2020, 47, 241-248.	2.0	24
14	Functional autoantibodies in systemic sclerosis. Seminars in Immunopathology, 2015, 37, 529-542.	6.1	23
15	Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis. Nutrients, 2020, 12, 1894.	4.1	23
16	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Research and Therapy, 2020, 22, 257.	3.5	20
17	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	1.9	20
18	Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathologica, 2021, 141, 917-927.	7.7	19

#	Article	IF	Citations
19	Monocytic Angiotensin and Endothelin Receptor Imbalance Modulate Secretion of the Profibrotic Chemokine Ligand 18. Journal of Rheumatology, 2016, 43, 587-591.	2.0	17
20	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, 2018, 70, 1829-1834.	5.6	15
21	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	1.9	14
22	Older age onset of systemic sclerosis â€" accelerated disease progression in all disease subsets. Rheumatology, 2020, 59, 3380-3389.	1.9	14
23	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Annals of the Rheumatic Diseases, 2019, 78, 1681-1685.	0.9	13
24	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 626-628.	0.9	12
25	Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. Archives of Rheumatology, 2019, 34, 253-261.	0.9	12
26	Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 2020, 79, 1123-1125.	0.9	11
27	Performance of ENMC and EULAR/ACR classification systems applied to a single tertiary center cohort of dermatomyositis patients. Neurological Research and Practice, 2021, 3, 59.	2.0	2
28	06.08â€¦Low-dose il-2 therapy in refractory sle: results from a single centre phase i/iia clinical trial. , 2017, , .		1
29	Does angiotensin and endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR database. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 154-155.	0.8	1
30	O36â€¦Low-dose IL-2 therapy modulates lymphocyte subsets that are involved in the regulation of germinal-centre reactions in patients with SLE. , 2020, , .		0
31	Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. Archives of Rheumatology, 2020, 35, 460-461.	0.9	0
32	Purinergic signaling in systemic sclerosis. Rheumatology, 2021, , .	1.9	0